129 related articles for article (PubMed ID: 38360213)
1. Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population.
Corren J; Szefler SJ; Sher E; Korenblat P; Soong W; Hanania NA; Berman G; Brusselle G; Zitnik R; Natalie CR; Sun L; Siu K; Wu WS; Lio P; Armstrong AW
J Allergy Clin Immunol Pract; 2024 May; 12(5):1215-1224.e3. PubMed ID: 38360213
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.
Hanania NA; Korenblat P; Chapman KR; Bateman ED; Kopecky P; Paggiaro P; Yokoyama A; Olsson J; Gray S; Holweg CT; Eisner M; Asare C; Fischer SK; Peng K; Putnam WS; Matthews JG
Lancet Respir Med; 2016 Oct; 4(10):781-796. PubMed ID: 27616196
[TBL] [Abstract][Full Text] [Related]
3. A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).
Austin CD; Gonzalez Edick M; Ferrando RE; Solon M; Baca M; Mesh K; Bradding P; Gauvreau GM; Sumino K; FitzGerald JM; Israel E; Bjermer L; Bourdin A; Arron JR; Choy DF; Olsson JK; Abreu F; Howard M; Wong K; Cai F; Peng K; Putnam WS; Holweg CTJ; Matthews JG; Kraft M; Woodruff PG;
Clin Exp Allergy; 2020 Dec; 50(12):1342-1351. PubMed ID: 32909660
[TBL] [Abstract][Full Text] [Related]
4. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.
Noonan M; Korenblat P; Mosesova S; Scheerens H; Arron JR; Zheng Y; Putnam WS; Parsey MV; Bohen SP; Matthews JG
J Allergy Clin Immunol; 2013 Sep; 132(3):567-574.e12. PubMed ID: 23726041
[TBL] [Abstract][Full Text] [Related]
5. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.
FitzGerald JM; Bleecker ER; Menzies-Gow A; Zangrilli JG; Hirsch I; Metcalfe P; Newbold P; Goldman M
Lancet Respir Med; 2018 Jan; 6(1):51-64. PubMed ID: 28919200
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
[TBL] [Abstract][Full Text] [Related]
7. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.
Busse WW; Wenzel SE; Casale TB; FitzGerald JM; Rice MS; Daizadeh N; Deniz Y; Patel N; Harel S; Rowe PJ; Graham NMH; O'Riordan T; Pavord ID
Lancet Respir Med; 2021 Oct; 9(10):1165-1173. PubMed ID: 34181876
[TBL] [Abstract][Full Text] [Related]
8. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
[TBL] [Abstract][Full Text] [Related]
9. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial.
Kelsen SG; Agache IO; Soong W; Israel E; Chupp GL; Cheung DS; Theess W; Yang X; Staton TL; Choy DF; Fong A; Dash A; Dolton M; Pappu R; Brightling CE
J Allergy Clin Immunol; 2021 Sep; 148(3):790-798. PubMed ID: 33872652
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of randomized controlled trials for the efficacy and safety of anti-interleukin-13 therapy with lebrikizumab in patients with uncontrolled asthma.
Liu Y; Zhang S; Chen R; Wei J; Guan G; Zhou M; Dong N; Cao Y
Allergy Asthma Proc; 2018 Sep; 39(5):332-337. PubMed ID: 30153886
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS).
Szefler SJ; Roberts G; Rubin AS; Zielen S; Kuna P; Alpan O; Anzures-Cabrera J; Chen Q; Holweg CTJ; Kaminski J; Putnam WS; Matthews JG; Kamath N
Clin Transl Allergy; 2022 Jul; 12(7):e12176. PubMed ID: 35846226
[TBL] [Abstract][Full Text] [Related]
12. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.
Scheerens H; Arron JR; Zheng Y; Putnam WS; Erickson RW; Choy DF; Harris JM; Lee J; Jarjour NN; Matthews JG
Clin Exp Allergy; 2014 Jan; 44(1):38-46. PubMed ID: 24131304
[TBL] [Abstract][Full Text] [Related]
13. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
14. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
15. Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma.
Zhu R; Zheng Y; Dirks NL; Vadhavkar S; Jin JY; Peng K; Holweg CTJ; Olsson J; Matthews JG; Putnam WS
Pulm Pharmacol Ther; 2017 Oct; 46():88-98. PubMed ID: 28843617
[TBL] [Abstract][Full Text] [Related]
16. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.
Hanania NA; Noonan M; Corren J; Korenblat P; Zheng Y; Fischer SK; Cheu M; Putnam WS; Murray E; Scheerens H; Holweg CT; Maciuca R; Gray S; Doyle R; McClintock D; Olsson J; Matthews JG; Yen K
Thorax; 2015 Aug; 70(8):748-56. PubMed ID: 26001563
[TBL] [Abstract][Full Text] [Related]
17. Lebrikizumab treatment in adults with asthma.
Corren J; Lemanske RF; Hanania NA; Korenblat PE; Parsey MV; Arron JR; Harris JM; Scheerens H; Wu LC; Su Z; Mosesova S; Eisner MD; Bohen SP; Matthews JG
N Engl J Med; 2011 Sep; 365(12):1088-98. PubMed ID: 21812663
[TBL] [Abstract][Full Text] [Related]
18. Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma.
Gallagher A; Edwards M; Nair P; Drew S; Vyas A; Sharma R; Marsden PA; Wang R; Evans DJ
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD012929. PubMed ID: 34664263
[TBL] [Abstract][Full Text] [Related]
19. Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials.
Stein Gold L; Thaçi D; Thyssen JP; Gooderham M; Laquer V; Moore A; Natalie CR; Zhao F; Meskimen E; Elmaraghy H; Montmayeur S; Gallo G; Jimenez G; de Bruin-Weller M
Am J Clin Dermatol; 2023 Jul; 24(4):595-607. PubMed ID: 37195407
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]